Arrowhead Research
Arrowhead Research is a publicly traded (NASDAQ: ARWR) pharmaceutical company that is a component of the NASDAQ Biotechnology Index.[1] Its products in development are at the cutting edge of RNA research and have the potential to make great strides in curing Hepatitis B,[2][3][4] and Carcinomare.[5][6] The company has 6 products in its pipeline, in various stages of clinical trials.
| Product | Indication | Development phase |
|---|---|---|
| ARC-520 | Hepatitis B | Phase II |
| ARC-521 | Hepatitis B | Pre-IND |
| ARC-AAT | Alpha-1 Antiryspin Deficiency | Phase I |
| ARC-F12 | Thrombosis | Pre-IND |
| ARC-HIF2 | Carcinomare | Pre-IND |
| ARC-LPA | Cardiovascular Disease | Pre-Clinical |
References[7]
- ↑ "Arrowhead Added to NASDAQ Biotechnology Index". WFLX. Retrieved 4 January 2016.
- ↑ "Arrowhead’s ARC-520 Leads to Consistent Immune Reactivation in Chimpanzees with Chronic Hepatitis B Infection". Reuters. Retrieved 4 January 2016.
- ↑ Calia, Michael. "FDA Informs Arrowhead of Partial Clinical Hold for Hepatitis B Drug". Wall Street Journal. Retrieved 4 January 2016.
- ↑ "ARC-520 hepbblog". wp.hepb.org. Hepatitis B Foundation.
- ↑ "Arrowhead Added to NASDAQ Biotechnology Index". WFLX. Retrieved 4 January 2016.
- ↑ "Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC™ Delivery System". Yahoo Finance. Retrieved 4 January 2016.
- ↑ "Arrowhead Research Corporation | Programs Overview". Arrowhead Research. Retrieved 4 January 2016.
This article is issued from Wikipedia - version of the Tuesday, January 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.